NLRP3 Deficiency Reduces Macrophage Interleukin-10 Production and Enhances the Susceptibility to Doxorubicin-induced Cardiotoxicity

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Kobayashi, Motoi ^a   Usui, Fumitake ^a   Karasawa, Tadayoshi ^a   Kawashima, Akira ^a   Kimura, Hiroaki ^a   Mizushina, Yoshiko ^a   Shirasuna, Koumei ^a   Mizukami, Hiroaki ^a   Kasahara, Tadashi ^a   Hasebe, Naoyuki ^b   Takahashi, Masafumi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; DOXORUBICIN; IL10 PROTEIN, MOUSE; IL1B PROTEIN, MOUSE; INTERLEUKIN 10; INTERLEUKIN 1BETA; NLRP3 PROTEIN, MOUSE;

ANIMAL; BONE MARROW TRANSPLANTATION; CARDIOTOXICITY; CELL CULTURE; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; GENETICS; HEART INJURY; HUMAN; IMMUNOLOGY; MACROPHAGE; METABOLISM; MOUSE;

ANIMALS; BONE MARROW TRANSPLANTATION; CARDIOTOXICITY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOXORUBICIN; HEART INJURIES; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; MACROPHAGES; MICE; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;

EID: 84971294354     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26489     Document Type: Article

References (36)

1. Singal, P. K., Iliskovic, N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339, 900-905 (1998).
2. Octavia, Y. et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52, 1213-1225 (2012).
3. Takemura, G., Fujiwara, H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49, 330-352 (2007).
4. Riad, A. et al. Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. Eur J Heart Fail 10, 233-243 (2008).
5. Nozaki, N., Shishido, T., Takeishi, Y., Kubota, I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 110, 2869-2874 (2004).
6. Latz, E., Xiao, T. S., Stutz, A. Activation and regulation of the inflammasomes. Nat Rev Immunol 13, 397-411 (2013).
7. Davis, B. K., Wen, H., Ting, J. P. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29, 707-735 (2011).
8. Takahashi, M. NLRP3 inflammasome as a novel player in myocardial infarction. Int Heart J 55, 101-105 (2014).
9. Kuida, K. et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267, 2000-2003 (1995).
10. Yajima, N. et al. Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. Circulation 117, 3079-3087 (2008).
11. Usui, F. et al. Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm. Arterioscler Thromb Vasc Biol 35, 127-136 (2015).
12. Usui, F. et al. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice. Biochem Biophys Res Commun 425, 162-168 (2012).
13. Kawaguchi, M. et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123, 594-604 (2011).
14. Sauter, K. A., Wood, L. J., Wong, J., Iordanov, M., Magun, B. E. Doxorubicin and daunorubicin induce processing and release of interleukin-1beta through activation of the NLRP3 inflammasome. Cancer Biol Ther 11, 1008-1016 (2011).
15. Zhu, J. et al. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol 643, 247-253 (2010).
16. Inoue, Y. et al. NLRP3 regulates neutrophil functions and contributes to hepatic ischemia-reperfusion injury independently of inflammasomes. J Immunol 192, 4342-4351 (2014).
17. Mizushina, Y. et al. NLRP3 protein deficiency exacerbates hyperoxia-induced lethality through stat3 protein signaling independent of interleukin-1beta. J Biol Chem 290, 5065-5077 (2015).
18. Saraiva, M., O'Garra, A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 10, 170-181 (2010).
19. Yoshioka, T. et al. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. Gene Ther 11, 1772-1779 (2004).
20. Ito, T. et al. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res 101, 734-741 (2007).
21. Shigeoka, A. A. et al. An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury. J Immunol 185, 6277-6285 (2010).
22. Bruchard, M. et al. The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat Immunol 16, 859-870 (2015).
23. Lech, M.,ers, H. J. Macrophages and fibrosis: How resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair. Biochim Biophys Acta 1832, 989-997 (2013).
24. Fujiu, K., Wang, J., Nagai, R. Cardioprotective function of cardiac macrophages. Cardiovasc Res 102, 232-239 (2014).
25. Hulsmans, M., Sam, F., Nahrendorf, M. Monocyte and macrophage contributions to cardiac remodeling. J Mol Cell Cardiol, doi: 10.1016/j.yjmcc.2015.11.015 (2015).
26. Verma, S. K. et al. Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-kappaB. Circulation 126, 418-429 (2012).
27. Krishnamurthy, P. et al. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res 104, e9-18 (2009).
28. Stumpf, C. et al. Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction. Eur J Heart Fail 10, 733-739 (2008).
29. Yang, Z., Zingarelli, B., Szabo, C. Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation 101, 1019-1026 (2000).
30. Ito, M. et al. Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun 6, 7360 (2015).
31. Schmidt, N. W., Thieu, V. T., Mann, B. A., Ahyi, A. N., Kaplan, M. H. Bruton's tyrosine kinase is required for TLR-induced IL-10 production. J Immunol 177, 7203-7210 (2006).
32. Marchetti, C. et al. Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse. J Cardiovasc Pharmacol 66, 1-8 (2015).
33. Ikeda, Y., Murakami, A., Ohigashi, H. Strain differences regarding susceptibility to ursolic acid-induced interleukin-1beta release in murine macrophages. Life Sci 83, 43-49 (2008).
34. Lamkanfi, M. et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 187, 61-70 (2009).
35. Horai, R. et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 187, 1463-1475 (1998).
36. Morimoto, H. et al. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res 99, 891-899 (2006).